Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Peptonic Medical AB is a Swedish-based biomedical company focused on the development and commercialization of health products for women. The company's primary function is to innovate within the feminine health sector, particularly targeting areas with significant unmet needs. Peptonic Medical AB has developed products using patented technologies aimed at improving women's reproductive and sexual health. A notable product from Peptonic is a line of hormone-free treatments designed to alleviate symptoms related to menopause and other conditions. This focus on non-hormonal therapeutic options places Peptonic Medical AB at the intersection of medical research and consumer health. As part of the growing biomedical industry, Peptonic contributes to advancements in women's health, leveraging expertise in biotechnology and consumer product distribution to fulfill its mission. The company operates primarily in Europe and seeks to expand its reach globally through strategic collaborations and partnerships.
kr 0.00
+kr 0.00 (+0.00%)
Price from 2 days ago
The business is unprofitable at the operating level (-131.52% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 45.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -kr 21M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 14M
▼ -45.0% YoY
Net Income (TTM)
-kr 21M
▲ +62.5% YoY
Op. Margin
-122.25%
▲ +19.5pp YoY
ROIC
-28.24%
▲ +15.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 18M
▲ +46.7% YoY
Op. Cash Flow (TTM)
-kr 11M
▲ +31.2% YoY
Net Debt
kr 9M
Cash & Equiv.
kr 195K
3Y CAGR: -30.3%
Continue Research
Peptonic Medical AB (PMED.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Peptonic Medical AB scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Peptonic Medical AB scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -122.2% operating margin and a -28.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh PMED.XSTO's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.